• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Safe Supply Streaming Begins Trading on the CSE

Microdose NewsDesk by Microdose NewsDesk
October 7, 2023
in Industry
Reading Time: 3 mins read
A A
Safe Supply Streaming Begins Trading on the CSE

With decriminalization efforts moving forward in many jurisdictions, and with clinical trials nearing government approval, ensuring safe and reliable supply of psychoactive compounds will be a crucial part of the industry’s future.

Enter Safe Supply Streaming. The company is investing in and incubating companies at the forefront of drug policy reform. From developing facilities to analyze, manufacture and distribute psychoactive compounds, to investing in research and constructing clinical infrastructure to ensure safe and responsible access and treatment.

The company went public on the CSE this week, the first publicly-traded company focused on the safe supply ecosystem. The stock went live on October 3 2023, under the trading symbol “SPLY”.

See the full press release below and stay tuned to Microdose for more on this.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

 

Continue on your trip...

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

Safe Supply Streaming Co. Ltd. to Begins Trading on the CSE, October 3, 2023

Trading Symbol: SPLY

Toronto, Ontario–(Newsfile Corp. – October 3, 2023) – Safe Supply Streaming Co. Ltd. (CSE: SPLY) (“Safe Supply” or “Company“), the first company investing in and incubating companies at the forefront of the third wave of drug policy reform, is pleased to announce it will begin trading on the Canadian Securities Exchange (the “CSE“) today, October 3 2023, under the trading symbol “SPLY“.

“The burgeoning safe supply ecosystem is more than just a business; it’s a movement,” said Bill Panagiotakopoulos, CEO of Safe Supply Streaming Co. “A global shift is underway where governments, policymakers and societies are making the decision to accept and embrace all drugs, whether through de-scheduling, re-scheduling or legalization because existing policies simply haven’t worked. Our strategic positioning and our experienced leadership team, backed by a robust financial foothold, positions us to move quickly on initiatives that will have impact and build a promising future that is not only profitable but also sustainable and responsible.”

A Glimpse into the Future

Safe Supply’s listing on the CSE comes on the cusp of a transformative era in health and wellness, as global drug policy moves from prohibition to regulation and access. At the time of listing, the Company has a robust financial cash base, and a strategy that aligns its success with pivotal drug policy reform movements – from the rescheduling of MDMA and psilocybin in Australia to the innovative legal supply policy initiatives in Switzerland to the globally leading safe supply programs in British Columbia.

Led by an executive leadership team of pioneers from the cannabis and psychedelics industries, Safe Supply has built a business model and strategy that is expected to yield substantial growth and advancements as the third wave of drug policy reform progresses. This strategy positions Safe Supply as a resolute voice and champion in the sector, leveraging the leadership team’s expertise to be first mover in the emerging global opportunities in the safe supply ecosystem.

As of October 3, 2023, SPLY has 70,217,750 common shares outstanding.

About Safe Supply

Purchase Lasix Via Mail

With a mission to help bring a responsible end to the war on drugs, Safe Supply Streaming Co. Ltd. is investing in and incubating companies at the forefront of the third wave of drug policy reform. As jurisdictions around the world move to decriminalize, regulate and legalize drugs, Safe Supply is investing in the infrastructure necessary to support the transition. From developing the facilities to analyze, manufacture and distribute psychoactive compounds including the coca plant, to investing in the research and innovation to harness the potential, and minimize the harm, of these medicines, to constructing the clinical infrastructure to ensure safe and responsible access and treatment, Safe Supply is building a platform of tightly woven companies that will help save millions of lives and build a safer, healthier post-war on drugs worlds.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Learn more at www.safesupply.com and follow Safe Supply on LinkedIn, Twitter, and Instagram.

For Further Information:

Bill Panagiotakopoulos
Chief Executive Officer and Director
Safe Supply Streaming Co. Ltd.
www.safesupplystreaming.com
bill@safesupply.com

Microdose NewsDesk

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Next Post
Breaking News: California Governor Vetoes Psychedelics Decriminalization Bill

Breaking News: California Governor Vetoes Psychedelics Decriminalization Bill

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.